Why the study?
Proinflammatory status is a risk factor for coronary atherosclerosis progression after coronary stenting, and the prognostic significance of preprocedural hsCRP reduction with intensive statin therapy needed evaluation.
Does intensive atorvastatin therapy reduce coronary atherosclerosis progression and hsCRP levels in patients with stable angina undergoing scheduled coronary stenting?
Does intensive atorvastatin therapy reduce coronary atherosclerosis progression and hsCRP levels in patients with stable angina undergoing scheduled coronary stenting?
Intensive atorvastatin therapy before and after coronary stenting significantly decreases hsCRP levels, though the full impact on atherosclerosis progression is unclear due to incomplete abstract text.
Intensive atorvastatin was associated with hsCRP reduction after stenting; hypothesis-generating for effects on atherosclerosis progression.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shchinova et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: